GlassScriptPhysician profile
James S Potter
NPI 1821001785
$3,118.23
in general payments reported to CMS, 2019-2025
15 companies · $538 in 2025
The $538 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $262 · 2021: $186 · 2022: $192 · 2023: $244 · 2024: $421 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,468.25 | 2019-2025 | Precision7, Total30, Rocklatan |
| Bausch & Lomb Americas INC. | $548.24 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Stryker Corporation | $191.35 | 2024-2025 | Mako |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.02 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $119.93 | 2020 | |
| Novartis Pharmaceuticals Corporation | $117.89 | 2019-2023 | |
| Allergan, INC. | $103.67 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $92.73 | 2019-2025 | |
| Oyster Point Pharma, INC. | $91.69 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $86.94 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $38.62 | 2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Abbvie INC. | $33.51 | 2023 | |
| Kala Pharmaceuticals, INC. | $28.69 | 2019-2021 | |
| Eyepoint US, INC. | $13.98 | 2019 | |
| Visioneering Technologies, INC. | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.